Enliven Therapeutics, Inc (ELVN) Tops Q2 EPS by 6c

Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q2 EPS of ($0.49), $0.06 better than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.

You May Also Be Interested In

• Goldman Sachs Adjust Monthly US Director's Cut List
• Scotiabank Starts Perpetua Resources (PPTA) at Sector Outperform
• BTIG Upgrades Tidewater Inc (TDW) to Buy, 'Increasing Activity Set To Push Dayrates Higher in Key Basins'